Mackay Shields LLC lifted its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 2.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,610 shares of the biopharmaceutical company’s stock after buying an additional 1,300 shares during the quarter. Mackay Shields LLC owned 0.08% of PTC Therapeutics worth $1,678,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of PTC Therapeutics by 2.1% in the second quarter. Vanguard Group Inc. now owns 5,070,674 shares of the biopharmaceutical company’s stock valued at $228,180,000 after buying an additional 102,485 shares in the last quarter. BlackRock Inc. raised its position in shares of PTC Therapeutics by 9.6% during the 2nd quarter. BlackRock Inc. now owns 4,502,671 shares of the biopharmaceutical company’s stock valued at $202,619,000 after acquiring an additional 394,773 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of PTC Therapeutics by 9.7% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,867,289 shares of the biopharmaceutical company’s stock valued at $174,028,000 after acquiring an additional 342,747 shares during the last quarter. Orbimed Advisors LLC raised its position in shares of PTC Therapeutics by 37.5% during the 2nd quarter. Orbimed Advisors LLC now owns 2,089,700 shares of the biopharmaceutical company’s stock valued at $94,037,000 after acquiring an additional 570,000 shares during the last quarter. Finally, Pictet Asset Management Ltd. raised its position in shares of PTC Therapeutics by 183.1% during the 2nd quarter. Pictet Asset Management Ltd. now owns 1,122,473 shares of the biopharmaceutical company’s stock valued at $50,511,000 after acquiring an additional 725,997 shares during the last quarter. Hedge funds and other institutional investors own 93.65% of the company’s stock.

PTC Therapeutics stock opened at $42.72 on Friday. The firm has a 50-day moving average of $37.50 and a 200-day moving average of $41.22. PTC Therapeutics, Inc. has a one year low of $27.53 and a one year high of $48.81. The company has a debt-to-equity ratio of 0.44, a current ratio of 4.40 and a quick ratio of 4.30. The company has a market cap of $2.57 billion, a price-to-earnings ratio of -23.22 and a beta of 1.88.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.91) by ($0.15). PTC Therapeutics had a negative return on equity of 31.92% and a negative net margin of 74.86%. The business had revenue of $71.40 million for the quarter, compared to analyst estimates of $72.03 million. During the same quarter in the prior year, the company earned ($1.06) earnings per share. The company’s quarterly revenue was up 33.2% on a year-over-year basis. As a group, sell-side analysts expect that PTC Therapeutics, Inc. will post -2.68 earnings per share for the current year.

A number of research firms recently commented on PTCT. Royal Bank of Canada restated a “buy” rating on shares of PTC Therapeutics in a research report on Tuesday, September 24th. Barclays restated a “hold” rating and issued a $43.00 price objective on shares of PTC Therapeutics in a research report on Monday, August 12th. Credit Suisse Group upped their price objective on shares of PTC Therapeutics from $54.00 to $58.00 and gave the company an “outperform” rating in a research report on Wednesday. Zacks Investment Research cut shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Finally, SunTrust Banks began coverage on shares of PTC Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $78.00 price objective for the company. Three research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $54.00.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.

Read More: What is Forex?

Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT).

Institutional Ownership by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.